We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · February 07, 2021

Effects of ACEI and ARB Continuation or Discontinuation on Outcomes in Patients With COVID-19

JAMA: The Journal of the American Medical Association

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial
JAMA 2021 Jan 19;325(3)254-264, RD Lopes, AVS Macedo, PGM de Barros E Silva, RJ Moll-Bernardes, TM Dos Santos, L Mazza, A Feldman, G D'Andréa Saba Arruda, DC de Albuquerque, AS Camiletti, AS de Sousa, TC de Paula, KGD Giusti, RAM Domiciano, MM Noya-Rabelo, AM Hamilton, VA Loures, RM Dionísio, TAB Furquim, FA De Luca, ÍB Dos Santos Sousa, BS Bandeira, CN Zukowski, RGG de Oliveira, NB Ribeiro, JL de Moraes, JLF Petriz, AM Pimentel, JS Miranda, BE de Jesus Abufaiad, CM Gibson, CB Granger, JH Alexander, OF de Souza

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading